Charity Williams

Cooley advised Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, in its strategic partnership with Kite, a Gilead Company (Nasdaq: GILD) to develop novel cell therapies across a variety of cancer targets. Under the terms of the agreement, Shoreline will receive an upfront payment and will be eligible to receive additional payments totaling over $2.3 billion as well as royalties based on achievement of certain development and commercial milestones.

Read more

Cooley advised Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases,  in its  exclusive worldwide strategic collaboration with BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a global biotechnology company, to develop and commercialize a portfolio of NK-based cell therapeutics with Shoreline’s iPSC NK cell technology and BeiGene’s research and clinical development capabilities for different malignancies. Under the terms of the agreement, Shoreline will receive an upfront cash payment of $45 million from BeiGene and will be eligible to receive additional R&D funding, milestone payments and royalties based upon the achievement of certain development, regulatory, and commercial milestones.  In connection with the agreement, BeiGene has an option to acquire an equity stake in Shoreline in its next round of equity financing, subject to specified conditions.

Read more

Cooley is advising Horizon Pharma on its acquisition of Crealta Holdings for $510 million in cash. The transaction, which is subject to the satisfaction of customary closing conditions and regulatory approvals, is anticipated to close in the first quarter of 2016.

"The Crealta acquisition further diversifies our portfolio of medicines and aligns with our focus of acquiring value-enhancing, clinically differentiated, long-life medicines that treat orphan diseases," said Timothy P Walbert, chairman, president and chief executive officer of Horizon Pharma.

Horizon Pharma, headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases.

Cooley has a longstanding relationship advising Horizon, including taking the company public in 2011. Earlier this year, Cooley advised Horizon on its acquisition of Hyperion Therapeutics for $1.1 billion, the company's largest acquisition to date. Cooley helped Horizon fund this acquisition through several equity and debt financings. In 2014, Cooley advised Horizon in its acquisition of Vidara Therapeutics for $660 million.

Cooley advised Horizon Pharma on its acquisition of River Vision and its development-stage eye medicine teprotumumab for approximately $145 million plus potential future milestone and earn-out payments.

Cooley advised Synthorx, a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, on its agreement to sell to Sanofi for approximately $2.5 billion. Partners Barbara Borden, Rama Padmanabhan and Ken Rollins led the Cooley team.